Cediranib for Metastatic Alveolar Soft Part Sarcoma

Kummar, Shivaani; Allen, Deborah; Monks, Anne; Polley, Eric C.; Hose, Curtis; Ivy, S. Percy; Türkbey, İsmail Barış; Lawrence, Scott M.; Kinders, Robert J.; Choyke, Peter L.; Simon, Richard; Steinberg, Seth M.; Doroshow, James H.; Helman, Lee J.

doi:10.1200/jco.2012.47.4288

Cited by 197 publications

(156 citation statements)

References 24 publications

Supporting

Mentioning

152

Contrasting

Order By: Relevance

“…Patients who had LMS, SS, ASPS, and vascular tumors reportedly were the main long‐term responders and survivors 13, 14. In particular, the activity of antiangiogenic agents, such as bevacizumab, sunitinib, and cediranib, was reported previously in ASPS 15, 16, 17. In addition to these tumors, we suggest that pazopanib may have the potential to allow patients with UPS and epithelioid sarcoma to achieve long SD and that there is less potential to achieve long SD in patients with LPS and MPNST.…”

Section: Discussionmentioning

confidence: 86%

The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study

Nakamura

Matsumine

Kawai

et al. 2016

Cancer

107

View full text Add to dashboard Cite

BACKGROUNDBecause the efficacy and safety of pazopanib in Japanese patients with soft tissue sarcoma (STS) had not been evaluated previously in a large‐scale cohort, the authors investigated the efficacy and safety of pazopanib in 156 Japanese patients with relapsed STS. This was a retrospective study based on the collection of real‐life, postmarketing surveillance data.METHODSPatients received pazopanib with the objective of treating local recurrence (n = 20), metastasis (n = 104), and both (n = 32). The patient median age was 53.8 years. The primary objective of this study was to clarify the efficacy of pazopanib for patients with STS.RESULTSThe median treatment duration was 28.7 weeks, and the average dose intensity of pazopanib was 609 mg. Adverse events occurred in 127 patients (81.4%). In addition to the main common toxicities, such as hypertension and liver disorder, pneumothorax (n = 11) and thrombocytopenia (n = 16) also were observed. The median progression‐free survival for all patients was 15.4 weeks. The median progression‐free survival for patients with leiomyosarcoma, synovial sarcoma, undifferentiated pleomorphic sarcoma, and liposarcoma was 18.6 weeks, 16.4 weeks, 15.3 weeks, and 8 weeks, respectively. The median survival for all patients was 11.2 months. The median survival for patients with leiomyosarcoma, synovial sarcoma, undifferentiated pleomorphic sarcoma, and liposarcoma was 20.1 months, 10.6 months, 9.5 months, and 7.3 months, respectively.CONCLUSIONSThere were apparent differences in the efficacy of pazopanib treatment among histologic types of STS. Pazopanib treatment is a new treatment option; however, adverse events like pneumothorax and thrombocytopenia, which did not occur frequently in the PALETTE study (pazopanib for metastatic soft‐tissue sarcoma), should be taken into consideration. Cancer 2016;122:1408‐16. © 2016 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society.

show abstract

Section: Discussionmentioning

confidence: 86%

The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study

Nakamura

Matsumine

Kawai

et al. 2016

Cancer

107

View full text Add to dashboard Cite

show abstract

“…Notably, the patient in the present case received 30 radiotherapy doses at 60 Gy per dose and was administered 4 courses of chemotherapy with doxorubicin and ifosfamide. According to previous prospective studies (13,14), cediranib, a recently developed molecular-target drug, may effectively treat ASPS associated with brain metastasis with an overall remission rate of up to 35% and 24-week control rate of 84%, thus providing a novel clinical treatment option.…”

Section: Discussionmentioning

confidence: 99%

Alveolar soft part sarcoma associated with lung and brain metastases: A case report

Wang

Huan

et al. 2016

Oncology Letters

View full text Add to dashboard Cite

Abstract. The present case report aimed to improve the understanding of alveolar soft part sarcoma (ASPS) by investigating the clinical characteristics, diagnosis and therapeutic methods used to treat ASPS associated with lung and brain metastases. The clinical data of a single patient diagnosed with ASPS by postoperative pathology was studied retrospectively, and additional associated reports and previous studies of similar cases were reviewed. Clinical symptoms were markedly alleviated following surgical treatment, followed by a chemotherapy regime. During post-treatment follow-up, no tumor recurrence was observed. IntroductionAlveolar soft part sarcoma (ASPS) is a clinically rare soft tissue sarcoma (STS) of unknown histological origin, accounting for 0.5-1.0% of all STS cases, worldwide (1). ASPS associated with lung and brain metastases is a rare disease with poor prognosis, with a high risk of metastasis to the brain. Surgery is typically the primary method used in the treatment of ASPS (2). The present study outlines the case of a patient with ASPS and associated lung and brain metastases. The patient provided signed informed consent, and therefore the case is detailed in the following report, including the course of disease and patient outcome. Case reportA 39-year-old male patient was admitted to the People's Hospital of Linyi City of Shandong Province (Linyi, China) on 3 January 2014, after experiencing occasional headaches during the previous 6 months. The patient's headaches had become progressively more severe 1 month prior to admission to hospital, and were associated with right upper limb weakness and inaccurate fine motor movements. Physical examination revealed negative cranial nerve-associated signs. Breath sounds were clear in both lungs, and no rhonchi or moist rales were heard. Distal right upper limb muscle strength received grade 4 (3), and tendon reflex and pathological signs were negative. As revealed by cranial computed tomography (CT; Fig. 1A), a high-density lesion was observed in the left postfrontal area [CT values, 52 Hounsfield units, (HU)] and a peripheral low-density edematous zone was visible. Magnetic resonance imaging (MRI) was also performed and revealed an irregular lump in the left frontal lobe with T1 and T2 hyperintensity. The surrounding vessels were belt-like and anfractuous with no intensified edematous regions (Fig. 1B-D). The medical history of the patient included resection of a subcutaneous mass in the left lower limb 10 years previously, which recurred 5 years later and required a second surgery. The masses resected during these earlier surgeries had not been sent for pathological examination. The patient reported no family history of the manifestations described above. Subsequently, the patient was further examined using chest radiography, which indicated multiple pulmonary nodules on both lungs. Therefore, the patient underwent single-photon emission CT/CT, which revealed no significant abnormalities on a whole-body bone scan (Fig. 1E). The chest CT result (Fig...

show abstract

“…The selection of a treatment plan largely depends on the tumor type and location. Currently, there is no effective standard systemic treatment for patients with unresectable ASPS [6] . For patients with cardiac metastases who have a limited life expectancy and a poor status, it is very important to keep treatment time as short as possible [10] .…”

Section: Discussionmentioning

confidence: 99%

“…Tumor resection is the main choice of treatment since standard cytotoxic chemotherapy regimens used for the treatment of soft tissue sarcomas are ineffective in treating ASPS [8] . Currently, there is no effective standard systemic treatment for patients with unresectable ASPS [6] .…”

Section: Introductionmentioning

confidence: 99%

“…The most common sites of metastases are the lung (38%), brain (33%), and bone (33%) [4] , and cardiac metastases from ASPS are rare [5] . ASPS is an indolent disease with characteristically slow growth, but it is associated with poor overall outcome and a 5-year survival rate of only 20% in unresectable metastatic patients [6,7] . Tumor resection is the main choice of treatment since standard cytotoxic chemotherapy regimens used for the treatment of soft tissue sarcomas are ineffective in treating ASPS [8] .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Cryoablation Combined with Iodine-125 Implantation in the Treatment of Cardiac Metastasis from Alveolar Soft Part Sarcoma: A Case Report

et al. 2016

View full text Add to dashboard Cite

Objectives: A 36-year-old Asian man was referred to our hospital with cardiac metastasis. He had a history of alveolar soft part sarcoma and initially underwent resection in 2005. Methods: After exposing the tumor by thoracotomy, cryoablation was performed under ultrasound guidance. This treatment was combined with iodine-125 seed implantation to treat the cardiac metastasis. Results: The patient had an uneventful recovery, and his cardiac function shows no obvious abnormalities. Imaging techniques suggest that cardiac metastasis was well controlled, and the patient is still alive 12 months after treatment. Conclusions: Tumor cryoablation, combined with iodine seed implantations, may be regarded as a means of palliative treatment. What Is It about?There is no effective standard systemic treatment for patients with unresectable aveolar soft part sarcoma (ASPS). Therefore, new locoregional and systemic therapies are needed. We present one of the first cases in which a patient with ASPS and cardiac metastases received palliative treatment comprising cryoablation with iodine-125 implantation. Follow-up and 1-year overall survival data indicate that the tumor was significantly controlled, and suggest that this treatment is effective. Further studies are warranted.

show abstract

Cediranib for Metastatic Alveolar Soft Part Sarcoma

Cited by 197 publications

References 24 publications

The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study

The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study

Alveolar soft part sarcoma associated with lung and brain metastases: A case report

Cryoablation Combined with Iodine-125 Implantation in the Treatment of Cardiac Metastasis from Alveolar Soft Part Sarcoma: A Case Report

Contact Info

Product

Resources

About